![Marc Schegerin](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Marc Schegerin
Director of Finance/CFO at
MORC HOLD
Profile
Marc Schegerin is currently Independent Director at SQZ Biotechnologies Co. since 2020.
Since 2020, also Chief Financial & Operating Officer at Morphic Therapeutic, Inc. and Chief Operating & Financial Officer at Morphic Holding, Inc. Formerly Program Director at Biogen, Inc. from 2009 to 2013.
Senior Director at SAGE Therapeutics, Inc. from 2013 to 2014.
Director at Citigroup, Inc. from 2016 to 2018.
Chief Financial Officer, Treasurer & Head-Strategy at ArQule, Inc. from 2019 to 2020.
Education includes undergraduate degrees from Tulane University (Louisiana) and Harvard University, a doctorate from Dartmouth Medical School, and an MBA from Tuck School of Business at Dartmouth.
Marc Schegerin active positions
| Companies | Position | Start |
|---|---|---|
| MORC HOLD | Director of Finance/CFO | 2020-04-05 |
| SQZ BIOTECHNOLOGIES COMPANY | Director/Board Member | 2020-10-22 |
Morphic Therapeutic, Inc.
 Morphic Therapeutic, Inc. BiotechnologyHealth Technology Researches and develops small molecules to block transmembrane integrin receptors | Director of Finance/CFO | 2020-03-31 |
Former positions of Marc Schegerin
| Companies | Position | End |
|---|---|---|
| ARQULE, INC. | Director of Finance/CFO | 2019-12-31 |
| CITIGROUP INC. | Director/Board Member | 2018-03-31 |
| SAGE THERAPEUTICS, INC. | Director/Board Member | 2013-12-31 |
| BIOGEN INC. | Corporate Officer/Principal | 2012-12-31 |
Training of Marc Schegerin
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
63
1st degree connections
11
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 11 |
|---|---|
Biogen, Inc.
 Biogen, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and markets therapies for neurological and neurodegenerative diseases | Health Technology |
ArQule, Inc.
 ArQule, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that researches and develops therapeutics to treat cancers & rare diseases | Health Technology |
Citigroup, Inc.
 Citigroup, Inc. Major BanksFinance Provides retail, investment, commercial banking, brand cards, securities sale & exchanges services | Finance |
SQZ Biotechnologies Co.
 SQZ Biotechnologies Co. BiotechnologyHealth Technology Operates as a clinical-stage biotechnology company that develops cell therapies for patients with cancer, infectious diseases and serious conditions | Health Technology |
Harvard University
 Harvard University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Tulane University (Louisiana)
 Tulane University (Louisiana) Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Dartmouth Medical School
 Dartmouth Medical School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Tuck School of Business at Dartmouth
 Tuck School of Business at Dartmouth Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
SAGE Therapeutics, Inc.
 SAGE Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes novel medicines for central nervous system disorders | Health Technology |
Morphic Therapeutic, Inc.
Morphic Therapeutic, Inc. BiotechnologyHealth Technology Researches and develops small molecules to block transmembrane integrin receptors | Health Technology |
Morphic Holding, Inc.
 Morphic Holding, Inc. Pharmaceuticals: MajorHealth Technology Develops oral integrin drugs | Health Technology |
- Stock Market
- Insiders
- Marc Schegerin
